| Item Type | Name |
|
Academic Article
|
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.
|
|
Academic Article
|
Ischemic optic neuropathy associated with low-dose interferon alfa: report of two cases.
|
|
Academic Article
|
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
|
|
Academic Article
|
Choroidal and conjunctival metastases from renal cell carcinoma.
|
|
Academic Article
|
Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon.
|
|
Academic Article
|
Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.
|
|
Academic Article
|
Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.
|
|
Academic Article
|
Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy.
|
|
Academic Article
|
Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis.
|
|
Academic Article
|
Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.
|
|
Concept
|
Kidney Medulla
|
|
Concept
|
Kidney Failure, Chronic
|
|
Concept
|
Kidney
|
|
Concept
|
Kidney Tubules, Collecting
|
|
Concept
|
Kidney Neoplasms
|
|
Academic Article
|
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies.
|
|
Academic Article
|
The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma.
|
|
Academic Article
|
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
|
|
Academic Article
|
Targeting hypoxia-inducible factor-1a (HIF-1a) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
|
|
Academic Article
|
Monitoring event times in early phase clinical trials: some practical issues.
|
|
Academic Article
|
Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Patient survival after surgery for osseous metastases from renal cell carcinoma.
|
|
Academic Article
|
Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma.
|
|
Academic Article
|
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
|
|
Academic Article
|
Renal cell carcinoma: diagnosis, staging, and surveillance.
|
|
Academic Article
|
Adjuvant and neoadjuvant therapy in renal cell carcinoma.
|
|
Academic Article
|
Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma.
|
|
Academic Article
|
Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures.
|
|
Academic Article
|
Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease.
|
|
Academic Article
|
Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays.
|
|
Academic Article
|
Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma.
|
|
Academic Article
|
Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?
|
|
Academic Article
|
Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes.
|
|
Academic Article
|
Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.
|
|
Academic Article
|
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
|
|
Academic Article
|
Mohs surgery in metastatic cancer: renal cell carcinoma solitary cutaneous metastasis and visceral tumor metastases to skin treated with microscopically controlled surgical excision.
|
|
Academic Article
|
Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
|
|
Academic Article
|
Re: Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study.
|
|
Academic Article
|
Joint association of genome-wide association study-identified susceptibility loci and dietary patterns in risk of renal cell carcinoma among non-Hispanic whites.
|
|
Academic Article
|
Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine?
|
|
Academic Article
|
Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings.
|
|
Academic Article
|
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
|
|
Academic Article
|
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Experience with sorafenib and the elderly patient.
|
|
Academic Article
|
Targeted therapy for locally advanced renal cell carcinoma.
|
|
Academic Article
|
Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.
|
|
Academic Article
|
Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Long-term management of patients with metastatic renal cell carcinoma on targeted agents.
|
|
Academic Article
|
Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.
|
|
Academic Article
|
Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib.
|
|
Academic Article
|
Emerging targeted therapies in metastatic renal cell carcinoma.
|
|
Academic Article
|
Adjuvant and neoadjuvant therapy in renal cell carcinoma.
|
|
Academic Article
|
Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases.
|
|
Academic Article
|
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
|
|
Academic Article
|
Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling.
|
|
Academic Article
|
Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
|
|
Academic Article
|
Curability of poor-risk metastatic sarcomatoid renal cell carcinoma with the combination of gemcitabine, 5-fluorouracil, and interferon-alfa: a case report of a 55-year-old man with a 10-year complete remission.
|
|
Academic Article
|
Randomized controlled trial of expressive writing for patients with renal cell carcinoma.
|
|
Academic Article
|
Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes.
|
|
Academic Article
|
Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer.
|
|
Academic Article
|
Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
|
|
Academic Article
|
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
|
|
Academic Article
|
Case-control analysis of nucleotide excision repair pathway and the risk of renal cell carcinoma.
|
|
Academic Article
|
Multisystem crisis in a patient with presumptive renal cell carcinoma.
|
|
Academic Article
|
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.
|
|
Academic Article
|
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Reply to Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies?
|
|
Academic Article
|
Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma.
|
|
Academic Article
|
Systemic therapy for sarcomatoid renal cell carcinoma.
|
|
Academic Article
|
Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.
|
|
Academic Article
|
Treatment-related optimism protects quality of life in a phase II clinical trial for metastatic renal cell carcinoma.
|
|
Academic Article
|
Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report.
|
|
Academic Article
|
Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.
|
|
Academic Article
|
Expression of OCT3/4 in renal medullary carcinoma represents a potential diagnostic pitfall.
|
|
Academic Article
|
Metastatic extraosseous Ewing's sarcoma (EES)/primitive neuroectodermal tumor (PNET) of the kidney: 8-year durable response after induction and maintenance chemotherapy.
|
|
Academic Article
|
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.
|
|
Academic Article
|
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.
|
|
Academic Article
|
Energy balance, polymorphisms in the mTOR pathway, and renal cell carcinoma risk.
|
|
Academic Article
|
Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.
|
|
Academic Article
|
Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring.
|
|
Academic Article
|
Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis.
|
|
Academic Article
|
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma.
|
|
Academic Article
|
Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment.
|
|
Academic Article
|
Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study.
|
|
Academic Article
|
Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results.
|
|
Academic Article
|
Sunitinib-induced acute hemolysis without hypertension: a case report.
|
|
Academic Article
|
Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.
|
|
Academic Article
|
Partial nephrectomy in the setting of metastatic renal cell carcinoma.
|
|
Academic Article
|
Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
|
|
Academic Article
|
Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience.
|
|
Academic Article
|
Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma: report of a case with unusual morphology and clinical follow-up.
|
|
Academic Article
|
Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes.
|
|
Academic Article
|
Psychological states, serum markers and survival: associations and predictors of survival in patients with renal cell carcinoma.
|
|
Academic Article
|
Autophagy mediates HIF2a degradation and suppresses renal tumorigenesis.
|
|
Academic Article
|
Neuroendocrine tumors of the kidney: a single institution experience.
|
|
Academic Article
|
Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing.
|
|
Academic Article
|
Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
|
|
Academic Article
|
Mitochondrial DNA copy number in peripheral blood leukocytes and the risk of clear cell renal cell carcinoma.
|
|
Academic Article
|
Role of partial nephrectomy as cytoreduction in the management of metastatic renal cell carcinoma.
|
|
Academic Article
|
Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent.
|
|
Academic Article
|
Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy.
|
|
Academic Article
|
Multilevel-analysis identify a cis-expression quantitative trait locus associated with risk of renal cell carcinoma.
|
|
Academic Article
|
Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation.
|
|
Academic Article
|
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy.
|
|
Academic Article
|
Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
|
|
Academic Article
|
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
|
|
Academic Article
|
Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell carcinoma.
|
|
Academic Article
|
High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.
|
|
Academic Article
|
DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas.
|
|
Academic Article
|
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
|
|
Academic Article
|
Outcomes of Adults With Ewing Sarcoma Family of Tumors (ESFT) of the Kidney
|
|
Academic Article
|
Renal Medullary Carcinoma: Establishing Standards in Practice.
|
|
Academic Article
|
HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas.
|
|
Academic Article
|
Cryoablation of Bone Metastases from Renal Cell Carcinoma for Local Tumor Control.
|
|
Academic Article
|
BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation.
|
|
Academic Article
|
Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma.
|
|
Academic Article
|
Outcomes of Adults With Ewing Sarcoma Family of Tumors (ESFT) of the Kidney: A Single-Institution Experience.
|
|
Academic Article
|
Proteinuria with first-line therapy of metastatic renal cell cancer.
|
|
Academic Article
|
Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases.
|
|
Academic Article
|
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
|
|
Academic Article
|
Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.
|
|
Academic Article
|
Single-fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma: secondary analysis of Phase I/II trials.
|
|
Academic Article
|
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
|
|
Academic Article
|
Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case-Control Study.
|
|
Academic Article
|
Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy.
|
|
Academic Article
|
The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis.
|
|
Academic Article
|
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.
|
|
Academic Article
|
Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support.
|
|
Academic Article
|
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
|
|
Academic Article
|
Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib.
|
|
Academic Article
|
Linking Gene Mutations to Clinical Outcomes and Response to Therapy in Clear-cell Renal Cell Carcinoma: Ready for Prime Time?
|
|
Academic Article
|
A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.
|
|
Academic Article
|
Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.
|
|
Academic Article
|
Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.
|
|
Academic Article
|
Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups.
|
|
Academic Article
|
MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity.
|
|
Academic Article
|
Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.
|
|
Academic Article
|
Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.
|
|
Academic Article
|
Recommendations for the Management of Rare Kidney Cancers.
|
|
Academic Article
|
Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.
|
|
Academic Article
|
Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities.
|
|
Academic Article
|
Papillary Renal Cell Carcinoma: A Family Portrait.
|
|
Academic Article
|
Potential Susceptibility Loci Identified for Renal Cell Carcinoma by Targeting Obesity-Related Genes.
|
|
Academic Article
|
Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
|
|
Academic Article
|
Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
|
|
Academic Article
|
NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas.
|
|
Academic Article
|
Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma.
|
|
Academic Article
|
First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy.
|
|
Academic Article
|
Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
|
|
Academic Article
|
Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.
|
|
Academic Article
|
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
|
|
Academic Article
|
Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome.
|
|
Academic Article
|
Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence.
|
|
Academic Article
|
Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.
|
|
Academic Article
|
Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
|
|
Academic Article
|
Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.
|
|
Academic Article
|
Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
|
|
Academic Article
|
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
|
|
Academic Article
|
Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma.
|
|
Academic Article
|
Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.
|
|
Academic Article
|
Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
|
|
Academic Article
|
Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma.
|
|
Academic Article
|
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
|
|
Academic Article
|
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma.
|
|
Academic Article
|
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.
|
|
Academic Article
|
Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.
|
|
Academic Article
|
Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC).
|
|
Academic Article
|
Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers.
|
|
Academic Article
|
Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.
|
|
Academic Article
|
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.
|
|
Academic Article
|
Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma.
|
|
Academic Article
|
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research.
|
|
Academic Article
|
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
|
|
Academic Article
|
Survival following cytoreductive nephrectomy: a comparison of existing prognostic models.
|
|
Academic Article
|
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
|
|
Academic Article
|
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
|
|
Academic Article
|
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
|
|
Academic Article
|
The Immunotherapy Revolution in Kidney Cancer Treatment: Scientific Rationale and First-Generation Results.
|
|
Academic Article
|
Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience.
|
|
Academic Article
|
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
|
|
Academic Article
|
Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials.
|
|
Academic Article
|
Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.
|
|
Academic Article
|
Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds.
|
|
Academic Article
|
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
|
|
Academic Article
|
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.
|
|
Academic Article
|
Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.
|
|
Academic Article
|
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
|
|
Academic Article
|
Real-world Clinical Effectiveness of Lenvatinib/Everolimus in a Heavily Pretreated Advanced/Metastatic Renal Cell Carcinoma Population in the US Community Oncology Setting.
|
|
Academic Article
|
Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.
|
|
Academic Article
|
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors.
|
|
Academic Article
|
Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma.
|
|
Academic Article
|
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
|
|
Academic Article
|
Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma.
|
|
Academic Article
|
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.
|
|
Academic Article
|
Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
|
|
Academic Article
|
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
|
|
Academic Article
|
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.
|
|
Academic Article
|
From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.
|
|
Academic Article
|
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
|
|
Academic Article
|
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.
|
|
Academic Article
|
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
|
|
Academic Article
|
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
|
|
Academic Article
|
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.
|
|
Academic Article
|
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma.
|
|
Academic Article
|
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
|
|
Academic Article
|
Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.
|
|
Academic Article
|
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas.
|
|
Academic Article
|
Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy.
|
|
Academic Article
|
SMARCB1 regulates the hypoxic stress response in sickle cell trait.
|
|
Academic Article
|
Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.
|
|
Academic Article
|
SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance.
|
|
Academic Article
|
Racial Disparities in MiT Family Translocation Renal Cell Carcinoma.
|
|
Academic Article
|
Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer.
|
|
Academic Article
|
Renal Cell Carcinoma of Variant Histology: Biology and Therapies.
|
|
Academic Article
|
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
|
|
Academic Article
|
SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma.
|
|
Academic Article
|
Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma.
|
|
Academic Article
|
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.
|
|
Academic Article
|
YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial.
|